SEPN Stock Forecast: Septerna, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Septerna, Inc. hold a median 12-month price target of $60 — +55.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 54 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Septerna, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (90): The shares have been drifting up relative to others.
Accruals (36): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SEPN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SEPN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +55.4% from it.
Of the 20 most recent actions, 10 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2026 | JP Morgan | Maintains | Overweight | $48 → $51 |
| 10 Nov 2026 | Stifel | Maintains | Buy | $49 → $60 |
| 6 Nov 2026 | Guggenheim | Maintains | Buy | $51 → $65 |
| 4 Nov 2026 | Wells Fargo | Maintains | Overweight | $50 → $61 |
| 19 Aug 2026 | JP Morgan | Maintains | Overweight | $38 → $48 |
| 13 Aug 2026 | Jones Trading | Maintains | Buy | $43 → $62 |
| 12 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $60 |
| 12 Aug 2026 | Wells Fargo | Maintains | Overweight | $48 → $50 |
| 11 Aug 2026 | Guggenheim | Maintains | Buy | $45 → $51 |
| 1 July 2026 | Guggenheim | Maintains | Buy | $52 → $45 |
| 1 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $40 |
| 1 July 2026 | Truist Securities | Maintains | Buy | $35 → $43 |
| 8 June 2026 | Raymond James | Maintains | Strong Buy | — |
| 13 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 11 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 3 Mar 2026 | Wells Fargo | Maintains | Overweight | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Mar 2026 | HC Wainwright& Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SEPN.
This page is one stock. Monday covers all of them.
SEPN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SEPN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Septerna, Inc. returned +62.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SEPN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 19.1×
- Price / book
- 4.3×
- EV / EBITDA
- —
Cheaper than 8% of US stocks
Cheaper than 22% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −76.2%
- Net margin
- —
Higher than 16% of US stocks
- Return on equity
- −14.4%
- Return on assets
- −7.5%
- Dividend yield
- —
Higher than 34% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Septerna, Inc. has a market value of $1.8B and an enterprise value of $1.4B.
Revenue in the twelve months to 30 June 2026: $98.9M. The latest quarter grew 22375.6% year on year.
Net income over the same four quarters: −$24.2M, a −24.5% net margin.
Diluted earnings per share, trailing twelve months: −$0.54.
Free cash flow in the twelve months to 30 June 2026: $105.1M.
Septerna, Inc. employs 134 people — $738K of revenue per employee.
Data provided by Twelve Data
SEPN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SEPN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Septerna, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SEPN
What is the SEPN stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Septerna, Inc. have a median 12-month price target of $60, with estimates ranging from $51 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SEPN stock a buy right now?
Of the 10 analysts covering Septerna, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Septerna, Inc. 54 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SEPN?
As at 21 Nov 2026, Septerna, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).
Will SEPN stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +55.4% from the last close, and Ticker Nerd's factor model ranks Septerna, Inc. 54 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SEPN stock forecast for 2030?
No analyst covering Septerna, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SEPN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $51 to $65 over the next 12 months.
How has SEPN stock performed over the past year?
Septerna, Inc. returned +62.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Septerna, Inc. do?
Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule therapies that target G protein-coupled receptors, or GPCRs. Its current programs address endocrine, immunology, inflammation, and metabolic disorders, with candidates under development for conditions such as hypoparathyroidism, chronic spontaneous urticaria, Graves’ disease, and thyroid eye disease.
About Septerna, Inc.
Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule therapies that target G protein-coupled receptors, or GPCRs. Its current programs address endocrine, immunology, inflammation, and metabolic disorders, with candidates under development for conditions such as hypoparathyroidism, chronic spontaneous urticaria, Graves’ disease, and thyroid eye disease. The company’s platform is designed to support the creation of medicines that can be taken by mouth, an approach that may improve treatment convenience across chronic disease areas. Septerna also advances research in metabolic and cardiometabolic biology through collaborations and internal drug discovery efforts. Headquartered in South San Francisco, California, Septerna operates within the biotechnology sector as a developer of experimental medicines aimed at hard-to-treat diseases.
CEO Dr. Jeffrey T. Finer M.D., Ph.D. · 134 employees · United States · https://www.septerna.com